OBJECTIVE: Translating lessons from clinical trials on the prevention or delay of type 2 diabetes to populations in nonstudy settings remains a challenge. The purpose of this paper is to review, from the perspective of practicing clinicians, available evidence on lifestyle interventions or medication to prevent or delay the onset of type 2 diabetes. DESIGN: A MEDLINE search identified 4 major diabetes prevention trials using lifestyle changes and 3 using prophylactic medications. We reviewed the study design, key components, and outcomes for each study, focusing on aspects of the interventions potentially adaptable to clinical settings. RESULTS: The lifestyle intervention studies set modest goals for weight loss and physical activity. Individualized counseling helped participants work toward their own goals; behavioral contracting and self-monitoring were key features, and family and social context were emphasized. Study staff made vigorous follow-up efforts for subjects having less success. Actual weight loss by participants was modest; yet, the reduction in diabetes incidence was quite significant. Prophylactic medication also reduced diabetes risk; however, lifestyle changes were more effective and are recommended as first-line strategy. Cost-effectiveness analyses have shown both lifestyle and medication interventions to be beneficial, especially as they might be implemented in practice. CONCLUSION: Strong evidence exists for the prevention or delay of type 2 diabetes through lifestyle changes. Components of these programs may be adaptable for use in clinical settings. This evidence supports broader implementation and increased reimbursement for provider services related to nutrition and physical activity to forestall morbidity from type 2 diabetes.
OBJECTIVE: Translating lessons from clinical trials on the prevention or delay of type 2 diabetes to populations in nonstudy settings remains a challenge. The purpose of this paper is to review, from the perspective of practicing clinicians, available evidence on lifestyle interventions or medication to prevent or delay the onset of type 2 diabetes. DESIGN: A MEDLINE search identified 4 major diabetes prevention trials using lifestyle changes and 3 using prophylactic medications. We reviewed the study design, key components, and outcomes for each study, focusing on aspects of the interventions potentially adaptable to clinical settings. RESULTS: The lifestyle intervention studies set modest goals for weight loss and physical activity. Individualized counseling helped participants work toward their own goals; behavioral contracting and self-monitoring were key features, and family and social context were emphasized. Study staff made vigorous follow-up efforts for subjects having less success. Actual weight loss by participants was modest; yet, the reduction in diabetes incidence was quite significant. Prophylactic medication also reduced diabetes risk; however, lifestyle changes were more effective and are recommended as first-line strategy. Cost-effectiveness analyses have shown both lifestyle and medication interventions to be beneficial, especially as they might be implemented in practice. CONCLUSION: Strong evidence exists for the prevention or delay of type 2 diabetes through lifestyle changes. Components of these programs may be adaptable for use in clinical settings. This evidence supports broader implementation and increased reimbursement for provider services related to nutrition and physical activity to forestall morbidity from type 2 diabetes.
Authors: L Ruggiero; J S Rossi; J O Prochaska; R E Glasgow; M de Groot; J M Dryfoos; G R Reed; C T Orleans; A V Prokhorov; K Kelly Journal: Addict Behav Date: 1999 Jul-Aug Impact factor: 3.913
Authors: J Eriksson; J Lindström; T Valle; S Aunola; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; M Lauhkonen; P Lehto; A Lehtonen; A Louheranta; M Mannelin; V Martikkala; M Rastas; J Sundvall; A Turpeinen; T Viljanen; M Uusitupa; J Tuomilehto Journal: Diabetologia Date: 1999-07 Impact factor: 10.122
Authors: William H Herman; Thomas J Hoerger; Michael Brandle; Katherine Hicks; Stephen Sorensen; Ping Zhang; Richard F Hamman; Ronald T Ackermann; Michael M Engelgau; Robert E Ratner Journal: Ann Intern Med Date: 2005-03-01 Impact factor: 25.391
Authors: L Fisher; C A Chesla; R J Bartz; C Gilliss; M A Skaff; F Sabogal; R A Kanter; C P Lutz Journal: Diabetes Educ Date: 1998 Sep-Oct Impact factor: 2.140
Authors: W Rakowski; B Ehrich; M G Goldstein; B K Rimer; D N Pearlman; M A Clark; W F Velicer; H Woolverton Journal: Prev Med Date: 1998 Sep-Oct Impact factor: 4.018
Authors: Edwin B Fisher; Marian L Fitzgibbon; Russell E Glasgow; Debra Haire-Joshu; Laura L Hayman; Robert M Kaplan; Marilyn S Nanney; Judith K Ockene Journal: Am J Prev Med Date: 2011-05 Impact factor: 5.043
Authors: John A Batsis; Abel Romero-Corral; Maria L Collazo-Clavell; Michael G Sarr; Virend K Somers; Francisco Lopez-Jimenez Journal: Mayo Clin Proc Date: 2008-08 Impact factor: 7.616
Authors: Abigail E Wilkes; Priya M John; Anusha M Vable; Amanda Campbell; Loretta Heuer; Cynthia Schaefer; Lisa Vinci; Melinda L Drum; Marshall H Chin; Michael T Quinn; Deborah L Burnet Journal: J Health Care Poor Underserved Date: 2013
Authors: Magnolia Cardona-Morrell; Lucie Rychetnik; Stephen L Morrell; Paola T Espinel; Adrian Bauman Journal: BMC Public Health Date: 2010-10-29 Impact factor: 3.295